Financial Management Professionals, Inc. Genmab A/S Transaction History

Financial Management Professionals, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 12, 2024	SELL	$27.94 - $35.44 $419 - $531	-15 Reduced 55.56%	12 $0
Q1 2023 Apr 13, 2023	BUY	$34.88 - $43.22 $523 - $648	15 Added 125.0%	27 $1,000
Q4 2022 Jan 11, 2023	SELL	$33.8 - $47.06 $709 - $988	-21 Reduced 63.64%	12 $1,000
Q3 2022 Oct 27, 2022	BUY	$31.52 - $373.61 $1,040 - $12,329	33 New	33 $1,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Financial Management Professionals, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Management Professionals, Inc. with notifications on news.